Revance to Participate in Upcoming Virtual Healthcare Conferences
Revance Therapeutics (Nasdaq: RVNC) announced that CEO Mark Foley will speak at two upcoming conferences. He will participate in the William Blair 41st Annual Growth Stock Conference on June 2, 2021, at 1:20 p.m. PT and the Goldman Sachs 42nd Annual Global Healthcare Conference on June 8, 2021, at 1:40 p.m. PT. Live audio webcasts will be accessible via the Investor Relations section of Revance's website, and a replay will be available for 30 days post-conference. Revance specializes in aesthetic and therapeutic offerings, including its innovative neuromodulator, DaxibotulinumtoxinA for Injection.
- None.
- None.
Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that the company’s President and Chief Executive Officer, Mark Foley, is scheduled to participate in fireside chats at the following conferences:
- The William Blair 41st Annual Growth Stock Conference on Wednesday, June 2, 2021 at 1:20 p.m. PT / 4:20 p.m. ET.
- The Goldman Sachs 42nd Annual Global Healthcare Conference on Tuesday, June 8, 2021 at 1:40 p.m. PT / 4:40 p.m. ET.
Interested parties can access the live audio webcast for this conference from the Investor Relations section of the company's website at www.revance.com. The webcast replay will be available after the conclusion of the live presentation for approximately 30 days.
About Revance Therapeutics, Inc.
Revance Therapeutics, Inc. is a biotechnology company focused on innovative aesthetic and therapeutic offerings, including its next-generation neuromodulator product, DaxibotulinumtoxinA for Injection. DaxibotulinumtoxinA for Injection combines a proprietary stabilizing peptide excipient with a highly purified botulinum toxin that does not contain human or animal-based components. Revance has successfully completed a Phase 3 program for DaxibotulinumtoxinA for Injection in glabellar (frown) lines and is pursuing U.S. regulatory approval. Revance is also evaluating DaxibotulinumtoxinA for Injection in the full upper face, including glabellar lines, forehead lines and crow's feet, as well as in two therapeutic indications - cervical dystonia and adult upper limb spasticity. To accompany DaxibotulinumtoxinA for Injection, Revance owns a unique portfolio of premium products and services for U.S. aesthetics practices, including the exclusive U.S. distribution rights to the RHA® Collection of dermal fillers, the first and only range of FDA-approved fillers for correction of dynamic facial wrinkles and folds, and the HintMD fintech platform, which includes integrated smart payment, subscription and loyalty digital services. Revance has also partnered with Viatris (formerly Mylan N.V.) to develop a biosimilar to BOTOX®, which would compete in the existing short-acting neuromodulator marketplace. Revance is dedicated to making a difference by transforming patient experiences. For more information or to join our team visit us at www.revance.com.
“Revance Therapeutics” and the Revance logo are registered trademarks of Revance Therapeutics, Inc.
Resilient Hyaluronic Acid® and RHA® are trademarks of TEOXANE SA.
BOTOX® is a registered trademark of Allergan, Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210526005318/en/
FAQ
When will Mark Foley speak at the William Blair Conference for Revance Therapeutics (RVNC)?
What is the date and time for Revance's participation in the Goldman Sachs Conference? RVNC?
Where can I access the live webcast for Revance Therapeutics (RVNC) conferences?
What is DaxibotulinumtoxinA for Injection offered by Revance (RVNC)?
How long will the conference webcasts for Revance Therapeutics (RVNC) be available?
